- Home
- Products
CALQUENCE (Acalabrutinib)
CALQUENCE (Acalabrutinib)
- Medicine Name: Calquence
- Generic Name: Acalabrutinib
- Dosage Form & Strength: Capsules – 100 mg
- Manufactured By: AstraZeneca Pharma
Calquence (Acalabrutinib) is a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of adult patients with:
- Mantle Cell Lymphoma (MCL) after at least one prior therapy
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Recommended Dosage:
- Monotherapy: 100 mg orally every 12 hours until disease progression or unacceptable toxicity
- Combination Therapy with Obinutuzumab (for untreated CLL/SLL):
- 100 mg orally every 12 hours, starting from Cycle 1
- Obinutuzumab to begin from Cycle 2 (each cycle = 28 days, for a total of 6 cycles)
- Calquence should be administered prior to Obinutuzumab on the same day
- 100 mg orally every 12 hours, starting from Cycle 1
Administration Instructions:
- Swallow capsules whole with water. Do not open, crush, or chew.
- Can be taken with or without food.
- If a dose is missed by more than 3 hours, skip and resume next scheduled dose. Do not double dose.
Infections (including severe or fatal) may occur. Monitor closely and initiate early treatment.
Hemorrhagic events, especially in patients using blood thinners. Monitor for signs of bleeding.
Cytopenias (neutropenia, anemia, thrombocytopenia, lymphopenia) may occur. Perform regular blood count monitoring.
Secondary malignancies, especially skin cancers, may occur. Sun protection is advised.
Atrial fibrillation/flutter: Monitor patients with cardiac risk factors for arrhythmia.
Pregnancy risk: Acalabrutinib may cause fetal harm. Effective contraception is necessary during treatment and for 7 days after the last dose.
Breastfeeding is not recommended during therapy and for 2 weeks after the last dose.
Use is not advised in patients with severe hepatic impairment.
To import Calquence (Acalabrutinib) via GlobalRareMeds, the following documents are required:
- Valid prescription from a qualified physician
- Diagnostic reports supporting treatment need
- Patient’s government-issued ID proof
Order Confirmation:
Orders are processed only after verification of documents and, if required, receipt of an import permit.
Calquence is a prescription-only medicine available under named-patient import regulations in India and abroad.
GlobalRareMeds sources Calquence (Acalabrutinib) through verified international suppliers based in the USA, Canada, Europe, and Australia.
Medicines are dispatched from our fulfillment center in Ambernath, Thane District, after pharmacist review and regulatory checks. Delivery is available across:
- Major Indian cities: Mumbai, Delhi, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Kolkata, and more
- International locations subject to local import regulations
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Calquence?
A. The generic name is Acalabrutinib.
Q. Who manufactures Calquence?
A. Calquence is manufactured by AstraZeneca Pharmaceuticals LP.
Q. Is Calquence FDA approved?
A. Yes, Calquence was approved by the FDA in January 2017.
Q. What form and strength is Calquence available in?
A. Calquence is supplied as 100 mg oral capsules.
Q. What conditions does Calquence treat?
A. Calquence is used in the treatment of CLL, SLL, and MCL.
Q. What are the most common side effects?
A. Side effects may include headache, neutropenia, anemia, diarrhea, musculoskeletal pain, infections, and thrombocytopenia.
Q. Can Calquence be taken during pregnancy or breastfeeding?
A. No. Calquence can cause fetal harm. Avoid use during pregnancy and breastfeeding. Use contraception during and for 7 days after treatment.
Q. How should Calquence be stored?
A. Store at 20–25°C (68–77°F); excursions permitted between 15–30°C (59–86°F).
Q. How can I access Calquence in India?
A. You can request Calquence through GlobalRareMeds. A valid prescription and compliance with documentation guidelines are mandatory.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
